Trial · NCT04209855
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | Mirvetuximab Soravtansine | 5.59 | 95% Confidence Interval 4.34 to 5.88 | months | |
| Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | Investigator's Choice (IC) Chemotherapy | 3.98 | 95% Confidence Interval 2.86 to 4.47 | months | |
| Objective Response Rate (ORR), as Assessed by the Investigator Using RECIST v1.1 | Mirvetuximab Soravtansine | 41.9 | 95% Confidence Interval 35.4 to 48.6 | percentage of participants | |
| Objective Response Rate (ORR), as Assessed by the Investigator Using RECIST v1.1 | Investigator's Choice (IC) Chemotherapy | 15.9 | 95% Confidence Interval 11.4 to 21.4 | percentage of participants | |
| Overall Survival Assessed by the Investigator Using RECIST v1.1 | Mirvetuximab Soravtansine | 16.85 | 95% Confidence Interval 14.36 to 19.78 | months | |
| Overall Survival Assessed by the Investigator Using RECIST v1.1 | Investigator's Choice (IC) Chemotherapy | 13.34 | 95% Confidence Interval 11.37 to 15.15 | months | |
Number of Participants Achieving at Least 15 Point Absolute Improvement in the Abdominal/Gastrointestinal (GI) Scale of European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Ovarian Cancer Module 28 (QLQ-OV28) | Mirvetuximab Soravtansine | 34 | Participants | ||
Number of Participants Achieving at Least 15 Point Absolute Improvement in the Abdominal/Gastrointestinal (GI) Scale of European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Ovarian Cancer Module 28 (QLQ-OV28) | Investigator's Choice (IC) Chemotherapy | 23 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Mirvetuximab Soravtansine | 211 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Investigator's Choice (IC) Chemotherapy | 194 | Participants | ||
| Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1 | Mirvetuximab Soravtansine | 6.93 | 95% Confidence Interval 5.78 to 8.84 | months | |
| Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1 | Investigator's Choice (IC) Chemotherapy | 4.44 | 95% Confidence Interval 4.17 to 5.75 | months | |
| Percentage of Participants With Cancer Antigen 125 (CA-125) Confirmed Clinical Response Per Gynecologic Cancer Intergroup (GCIG) Criteria | Mirvetuximab Soravtansine | 58.0 | 95% Confidence Interval 50.5 to 65.3 | percentage of participants | |
| Percentage of Participants With Cancer Antigen 125 (CA-125) Confirmed Clinical Response Per Gynecologic Cancer Intergroup (GCIG) Criteria | Investigator's Choice (IC) Chemotherapy | 30.1 | 95% Confidence Interval 23.1 to 38.0 | percentage of participants | |
| Time to Second Progression-Free Survival (PFS 2) | Mirvetuximab Soravtansine | 11.01 | 95% Confidence Interval 9.30 to 12.02 | months | |
| Time to Second Progression-Free Survival (PFS 2) | Investigator's Choice (IC) Chemotherapy | 7.59 | 95% Confidence Interval 6.60 to 8.84 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04209855/results